NCT00335504View on ClinicalTrials.gov

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Colon CancerPrecancerous ConditionRectal Cancer
Interventions
DRUG

oligofructose-enriched inulin

Given orally

DRUG

sulindac

Given orally

DRUG

placebo

Given orally

DRUG

atorvastatin calcium

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00335504 - Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia | Biotech Hunter | Biotech Hunter